Lvm Capital Management LTD Cyma Bay Therapeutics, Inc. Transaction History

Lvm Capital Management LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Apr 17, 2023	BUY	$5.88 - $9.59 $76,440 - $124,670	13,000 Added 130.0%	23,000 $200,000
Q2 2022 Jul 14, 2022	BUY	$1.72 - $3.39 $17,200 - $33,900	10,000 New	10,000 $29,000
Q4 2021 Jan 04, 2022	SELL	$3.23 - $4.6 $48,450 - $69,000	-15,000 Closed	0 $0
Q1 2021 Apr 06, 2021	SELL	$4.23 - $6.55 $4,230 - $6,550	-1,000 Reduced 6.25%	15,000 $68,000
Q1 2019 Apr 05, 2019	SELL	$8.16 - $13.42 $81,600 - $134,200	-10,000 Reduced 38.46%	16,000 $0
Q2 2018 Jul 10, 2018	BUY	$10.66 - $14.38 $53,300 - $71,900	5,000 Added 23.81%	26,000 $0
Q3 2017 Oct 16, 2017	BUY	$5.95 - $8.26 $124,950 - $173,460	21,000	21,000 $0

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Lvm Capital Management LTD, based on Form 13F filings with the SEC.

Stay updated on Lvm Capital Management LTD with notifications on news.